34results about How to "Inhibition of expression" patented technology

The invention relates to the technical field of medicine and discloses a phenylpropanoid compound and application of pharmaceutically acceptable salt thereof to preparing drugs for treating inflammatory diseases. The phenylpropanoid compound can suppress the expression effects of cell inflammatory factors TNF-alpha, IL-1beta and IL-6 and has a suppressing effect on (-OH) of hydroxyl radicals so that anti-inflammatory and anti-oxidant activity can be achieved, and direction is provided for development of drugs for treating inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis. Please see the structural formula in the description.

The invention relates to the technical field of medicines, and discloses an application of phenylpropanoids compounds in preparation of medicines for treating inflammatory diseases. The phenylpropanoid compounds are indicated to be able to inhibit expression effects of inflammatory cytokines TNF-alpha, IL-1beta and IL-6, thereby having anti-inflammatory activity, and providing a direction for development of medicines for treating inflammatory diseases, such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis and other diseases.

The invention relates to the technical field of medicines and discloses a phenylpropanoid compound and application of a pharmaceutically-acceptable salt thereof in preparation of medicines for treating inflammatory diseases. The phenylpropanoid compound can have the effects of inhibiting the content of a cellar inflammatory factor NO and expressing a cellar inflammatory factor TNF-alpha, has the inhibiting effect on hydroxyl radicals (-OH), further has anti-inflammatory and antioxidant activities and provides the development direction for the medicines for treating the inflammatory diseases, such as cervicitis, endometritis, pelvic inflammatory, mastitis, sphagitis and / or arthritis.

The invention discloses a phenylpropanoid compound and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition, belonging to the field of medical technology. The structure of the phenylpropanoid compound is as shown in a formula (I) which is described in the specification; and the structure of the pharmaceutically acceptable salt is as shown in a formula (II) or formula (III) which is described in the specification. The phenylpropanoid compound and the pharmaceutically acceptable salt thereof are capable of inhibiting the content of the inflammation cytokine NO and expression of the inflammation cytokines TNF-alpha, IL-1beta and IL-6 and exerts inhibitory effect on hydroxyl radicals (-OH), so the phenylpropanoid compound and the pharmaceutically acceptable salt thereof have anti-inflammatory and anti-oxidation activity and have good application prospect in preparation of drugs used for treating inflammatory diseases related to the inflammation cytokines, e.g., cervicitis, endometritis, pelvic inflammation, mastitis, pharyngolaryngitis and / or arthritis.

The invention discloses a drug for preventing and treating atherosclerotic plaque by adopting methods for removing wind, expelling phlegm and detoxifying, and a preparation method of the drug. The product formula comprises the following raw materials by weight: 3-5g of scorpio, 2-4g of centipede, 10-15g of earthworm, 10-15g of leech, 10-15g of pericarpium citri reticulatae, 10-15g of pinellia ternate, 10-15g of bighead atractylodes rhizome and 10-15g of honeysuckle. The preparation method comprises the following steps: soaking the scorpio, the centipede, the earthworm, the leech, the pericarpium citri reticulatae, the pinellia ternate, the bighead atractylodes rhizome and the honeysuckle for 40 minutes by 15-fold water; decocting by a slow fire for 70 minutes for the first time; adding 10fold water to decoct by the slow fire for 50 minutes for the second time; adding 6-fold water to decoct by the slow fire for 30 minutes for the third time; merging the decocted liquors of three times; filtering the obtained liquor by a gauze; concentrating by a water bath at 100 DEG C into 200ml of liquor after filtering, so as to obtain the product. The drug disclosed by the invention is simple in component, accurate in compatibility relationship, few in drugs, low in price, and accurate and significant in curative effect. The animal experiment proves that the drug has significant effects of preventing and treating arteriosclerosis, and adjusting blood fat, and is easily accepted by a sufferer.

The invention relates to the technical field of medicines, discloses a preparation method of a phenylpropanoid compound, and particularly relates to a phenylpropanoid compound which is obtained by being separated from dried roots of moghania macrophylla (Willd.) O Ktze.. The phenylpropanoid compound is prepared through the steps of solvent extraction, column chromatographic separation and liquid phase preparation, separation and purification. The phenylpropanoid compound obtained through the method is reported for the first time and is high in purity. It is proved through experiments that the obtained novel phenylpropanoid compound can inhibit expression effects of cell inflammatory factors of TNF-alpha, IL-1 beta and IL-6, has an inhibiting effect on hydroxyl free radicals (-OH), has anti-inflammatory and antioxidant activities, is beneficial for treatment of various inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, faucitis and / or arthritis and can be developed into a novel drug. The compound is the phenylpropanoid compound with the structural formula as shown in a formula (I) and pharmaceutically acceptable salts thereof. Please see the formula (I) in the description.

The invention relates to the technical field of medicine and discloses a preparation method of a phenylpropanoid compound. The invention particularly relates to a method for separating a phenylpropanoid compound from dried root of flemingia macrophylla, and the phenylpropanoid compound is prepared by steps of solvent extraction, column chromatography separation and preparation of liquid-phase separation for purification. The phenylpropanoid compound obtained by the method disclosed by the invention is reported for the first time and has high purity. Proven by experiments, the obtained new phenylpropanoid compound has an effects on inhibiting the content of cell inflammatory factor NO, inhibiting expression of cell inflammatory factors IL-1 beta and IL-6 and inhibiting hydroxyl free radical (-OH), thereby having anti-inflammatory and oxidation resisting activities and benefiting treatment of cervicitis, endometritis, pelvic inflammation, mastitis, faucitis and / or arthritis and various inflammatory diseases. The phenylpropanoid compound can be developed into a new drug. The structural formula of the phenylpropanoid compound disclosed by the invention is as shown in formula (I) in the specification.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to application of Pien Tze Huang and a preparation thereof in preparation of a medicine for resisting enterovirus EV71 infection. The invention discloses application of the Pien Tze Huang in preparation of the medicine for resisting enterovirus EV71 infection, and antiviral activity research on the application shows that the Pien Tze Huang significantly inhibits cytopathy, inhibits virus replication and reduces the virus particle loading capacity in the enterovirus EV71 infection process and has higheranti-EV71 virus activity, and a scientific basis is provided for the new application of the Pien Tze Huang.

The invention relates to the technical field of medicine, and discloses application of a phenylpropanoids compound to preparation of drugs for treating inflammation diseases. The phenylpropanoids compound can inhibit the content of cell inflammatory factors NO and inhibit expression of cell inflammatory factors IL-1beta and IL-6, has an inhibition effect on hydroxyl radicals (-OH) and has anti-inflammatory and antioxidant activity, and the direction is provided for developing the drugs for treating cervicitis, endometritis, pelvic inflammatory disease, mastitis, sphagitis and / or arthritis.

The invention relates to the technical field of medicines, discloses a preparation method of a phenylpropanoid compound, and particularly relates to a phenylpropanoid compound which is obtained by being separated from dried roots of moghania macrophylla (Willd.) O Ktze.. The phenylpropanoid compound is prepared through the steps of solvent extraction, column chromatographic separation and liquid phase preparation, separation and purification. The phenylpropanoid compound obtained through the method is reported for the first time and is high in purity. It is proved through experiments that the obtained novel phenylpropanoid compound can inhibit expression effects of cell inflammatory factors of TNF-alpha, IL-1 beta and IL-6, has an inhibiting effect on hydroxyl free radicals (-OH), has anti-inflammatory and antioxidant activities, is beneficial for treatment of various inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, faucitis and / or arthritis and can be developed into a novel drug. The compound is the phenylpropanoid compound with the structural formula as shown in a formula (I) and pharmaceutically acceptable salts thereof. Please see the formula (I) in the description.

The invention relates to the technical field of medicines and discloses a phenylpropanoid compound and a pharmaceutical composition thereof. The phenylpropanoid compound is shown as structural formula (I). The phenylpropanoid compound is capable of inhibiting content of inflammatory cytokines NO and expression of inflammatory cytokines IL-1beta and IL-6, plays a role in inhibiting hydroxyl radicals (-OH) to further have anti-inflammatory effect and antioxidant activity, and has a promising application prospect on preparation of medicines for treating various inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis associated to the inflammatory cytokines NO, IL-1beta and IL-6.

The invention relates to the technical field of medicine, and discloses phenylpropanoids, and pharmaceutically acceptable salts and a pharmaceutical composition thereof. The structure of the phenylpropanoids is disclosed as Formula (I), and the structure of the pharmaceutically acceptable salts is disclosed as Formula (II) or Formula (III). The phenylpropanoids and pharmaceutically acceptable salts thereof have the action of inhibiting expression of cell inflammatory factors TNF-alpha, IL-1beta and IL-6, have the inhibiting action on hydroxy free radicals (-OH), further have anti-inflammatory and antioxidation activities, and thus, have favorable application prospects in preparing drugs for treating diseases related to the factors above, such as cervicitis, endometritis, pelvic inflammation, mastitis, faucitis, arthritis and / or other inflammation diseases.

The invention relates to technical field of medicine, discloses a preparation method of a phenylpropanoid compound, and particularly relates to a phenylpropanoid compound obtained by being separated from dry roots of flemingia macrophylla. The phenylpropanoid compound is prepared through solution extraction, column chromatography separation and separation of a preparation liquid phase, and the phenylpropanoid compound obtained through the method is reported for the first time and high in purity. Experiments show that the obtained phenylpropanoid compound can suppress the expression effects of cell inflammatory factors TNF-alpha, IL-1beta and IL-6 and has a suppressing effect on (-OH) of hydroxyl radicals so that anti-inflammatory and anti-oxidant activity can be achieved, various inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis can be treated easily, and the compound can be developed into new drugs. The phenylpropanoid compound as shown in the structural formula (I) and pharmaceutically acceptable salt thereof are provided. Please see the structural formula (I) in the description.

The invention discloses a method for preparing hepatitis B Shukang capsules. The method comprises the following steps: performing water extraction on radix astragali, concentrating and drying an extract to fine powder A, merging herb residue with phyllanthus urinaria, red sage root, heydyotis, gentrin knotweed, and fleece-flower root, extracting the materials by ethanol with concentration being 70%, concentrating and drying the extract to fine powder B, uniformly mixing the fine powder A and the fine powder B, performing one-step granulation, and placing the product in the capsules to obtain the hepatitis B Shukang capsules. According to the invention, extraction by grouping is employed, the effective components can be enriched, the product curative effect is increased, and a purpose of reducing an administration amount is achieved. Compared with an original technology group, under condition that the administration amount of the prepared hepatitis B Shukang capsules is reduced by 20%,the inhibiting effect of the hepatitis B Shukang capsules for expression effect of HepG2-2.2.15 cells HBsAg and HBeAg and protection effect for chronic liver injury (a CC14 model) is stronger than that of an original technology.

The invention relates to the technical field of medicine, and discloses application of a phenylpropanoids compound to preparation of drugs for treating inflammation diseases. The phenylpropanoids compound can inhibit the content of cell inflammatory factors NO and inhibit expression of cell inflammatory factors IL-1beta and IL-6, has an inhibition effect on hydroxyl radicals (-OH) and has anti-inflammatory and antioxidant activity, and the direction is provided for developing the drugs for treating cervicitis, endometritis, pelvic inflammatory disease, mastitis, sphagitis and / or arthritis.

The invention discloses a phenylpropanoid compound and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition, belonging to the field of medical technology. The structure of the phenylpropanoid compound is as shown in a formula (I) which is described in the specification; and the structure of the pharmaceutically acceptable salt is as shown in a formula (II) or formula (III) which is described in the specification. The phenylpropanoid compound and the pharmaceutically acceptable salt thereof are capable of inhibiting the content of the inflammation cytokine NO and expression of the inflammation cytokines TNF-alpha, IL-1beta and IL-6 and exerts inhibitory effect on hydroxyl radicals (-OH), so the phenylpropanoid compound and the pharmaceutically acceptable salt thereof have anti-inflammatory and anti-oxidation activity and have good application prospect in preparation of drugs used for treating inflammatory diseases related to the inflammation cytokines, e.g., cervicitis, endometritis, pelvic inflammation, mastitis, pharyngolaryngitis and / or arthritis.

The invention relates to the technical field of medicine, and discloses application of a phenylpropanoid compound and medically-acceptable salt thereof in preparing medicine for treating inflammatory diseases. The phenylpropanoid compound shows the effect of inhibiting expression of inflammatory cytokines TNF-alpha, IL-1beta and IL-6 and has an inhibiting effect on hydroxyl radicals (-OH), and thus the phenylpropanoid compound has anti-inflammatory activity and anti-oxidative activity and provides direction for development of medicine for treating inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis.

The invention relates to technical field of medicine, discloses a preparation method of a phenylpropanoid compound, and particularly relates to a phenylpropanoid compound obtained by being separated from dry roots of flemingia macrophylla. The phenylpropanoid compound is prepared through solution extraction, column chromatography separation and separation of a preparation liquid phase, and the phenylpropanoid compound obtained through the method is reported for the first time and high in purity. Experiments show that the obtained phenylpropanoid compound can suppress the expression effects of cell inflammatory factors TNF-alpha, IL-1beta and IL-6 and has a suppressing effect on (-OH) of hydroxyl radicals so that anti-inflammatory and anti-oxidant activity can be achieved, various inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis can be treated easily, and the compound can be developed into new drugs. The phenylpropanoid compound as shown in the structural formula (I) and pharmaceutically acceptable salt thereof are provided. Please see the structural formula (I) in the description.

The invention relates to the technical field of medicine and discloses a phenylpropanoid compound and application of pharmaceutically acceptable salt thereof to preparing drugs for treating inflammatory diseases. The phenylpropanoid compound can suppress the expression effects of cell inflammatory factors TNF-alpha, IL-1beta and IL-6 and has a suppressing effect on (-OH) of hydroxyl radicals so that anti-inflammatory and anti-oxidant activity can be achieved, and direction is provided for development of drugs for treating inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis. Please see the structural formula in the description.

The invention relates to a siRNA molecule for interfering the expression of a Bcl-2 gene and application thereof. The positive chain of the siRNA molecule is SEQ ID NO:1, and the negative chain is SEQ ID NO:2, wherein the negative chain can be specifically combined with the mRNA of the Bcl-2 gene to degrade the mRNA so as to interfere a translation process after interference transcription and achieve the purpose of resisting tumors.

The invention relates to the technical field of medicines and discloses a phenylpropanoid compound and medically acceptable salts and pharmaceutical compositions thereof. A structural formula (I) of the phenylpropanoid compound is as shown in the specification, and a structural formula (II) or (III) of the medically acceptable salts is as shown in the specification. The phenylpropanoid compound and the medically acceptable salts thereof have an inhibition effect on content of inflammatory cytokines NO and expression of inflammatory cytokines TNF-alpha, has an inhibition effect on hydroxyl radical (-OH), further has anti-inflammatory and antioxidant activity and has a promising application prospect in preparation of medicines for treating inflammatory diseases including cervicitis, endometritis, pelvic inflammation, mastitis, faucitis, arthritis and / or the like related to the cytokines.

The invention relates to the technical field of medicines, discloses a phenylpropanoid compound preparation method and particularly relates to a phenylpropanoid compound separated from dry roots of Moghania macrophylla (Willd.) O.Ktze.. The phenylpropanoid compound is obtained by solvent extraction, column chromatography separation and preparative liquid phase separation and purification. The phenylpropanoid compound prepared by the preparation method is put forward for the first time and is high in purity.Experiments prove that the novel phenylpropanoid compound is capable of inhibiting content of inflammatory cytokines NO and expression of inflammatory cytokines TNF (tumor necrosis factor)-alpha and plays a role in inhibiting hydroxyl radicals (-OH) to further have anti-inflammatory effect and antioxidant activity and benefit treatment of various inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis, thereby being developed into novel medicines. The phenylpropanoid compound shown as structural formula (I) and pharmaceutically acceptable salts thereof are prepared.

The invention relates to the technical field of drugs, and discloses an application of phenylpropanoids compounds and pharmaceutically acceptable salts in preparation of drugs for treating inflammation diseases. The phenylpropanoids compounds can inhibit the content of a cell inflammatory factor NO, inhibits expressive effects of cell inflammatory factors TNF-alpha, IL-1beta and IL-6, has an inhibition effect on hydroxyl radicals (-OH), has anti-inflammatory and antioxidant activities, and provides a direction for development of the drugs for treating inflammation diseases, such as cervicitis, endometritis, pelvic inflammatory disease, mastitis, pharyngolaryngitis and / or arthritis and other diseases.

The invention relates to the technical field of medicines and discloses a phenylpropanoid compound and application of a pharmaceutically-acceptable salt thereof in preparation of medicines for treating inflammatory diseases. The phenylpropanoid compound can have the effects of inhibiting the content of a cellar inflammatory factor NO and expressing a cellar inflammatory factor TNF-alpha, has the inhibiting effect on hydroxyl radicals (-OH), further has anti-inflammatory and antioxidant activities and provides the development direction for the medicines for treating the inflammatory diseases, such as cervicitis, endometritis, pelvic inflammatory, mastitis, sphagitis and / or arthritis.

The invention relates to the technical field of medicine, and discloses phenylpropanoids, and pharmaceutically acceptable salts and a pharmaceutical composition thereof. The structure of the phenylpropanoids is disclosed as Formula (I), and the structure of the pharmaceutically acceptable salts is disclosed as Formula (II) or Formula (III). The phenylpropanoids and pharmaceutically acceptable salts thereof have the action of inhibiting expression of cell inflammatory factors TNF-alpha, IL-1beta and IL-6, have the inhibiting action on hydroxy free radicals (-OH), further have anti-inflammatory and antioxidation activities, and thus, have favorable application prospects in preparing drugs for treating diseases related to the factors above, such as cervicitis, endometritis, pelvic inflammation, mastitis, faucitis, arthritis and / or other inflammation diseases.

The invention relates to the technical field of medicine, and discloses application of a phenylpropanoid compound and medically-acceptable salt thereof in preparing medicine for treating inflammatory diseases. The phenylpropanoid compound shows the effect of inhibiting expression of inflammatory cytokines TNF-alpha, IL-1beta and IL-6 and has an inhibiting effect on hydroxyl radicals (-OH), and thus the phenylpropanoid compound has anti-inflammatory activity and anti-oxidative activity and provides direction for development of medicine for treating inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis.

The invention discloses a preparation method of Yigan Shukang Capsules. Firstly, astragalus is extracted with water, the extract is concentrated and dried into fine powder A, and the dregs are combined with phylloxera, salvia miltiorrhiza, hedyotis diffusa, polygonum cuspidatum and fleece-flower root, and 70% Extract with ethanol, concentrate and dry the extract into fine powder B, mix fine powder A and fine powder B evenly, granulate in one step, and pack into capsules to obtain Yigan Shukang Capsules. The present invention adopts group extraction, which can enrich the active ingredients, thereby improving the curative effect of the product and reducing the dosage. Compared with the original process group, the Yigan Shukang Capsules prepared by the method of the present invention can reduce the dosage by 20%. The effect of inhibiting the expression of HBsAg and HBeAg in HepG2-2.2.15 cells and the protective effect on chronic liver injury (CCl4 model) are still stronger than the original process.